Intellia VP, Cell Therapy, Birgit Schultes will be at #ASH20 tomorrow presenting new preclinical data supporting our #CRISPR/Cas9-engineered TCR-T cell treatment for #AcuteMyeloidLeukemia. #celltherapy #genomeediting #AML $NTLA @ASH_hematology https://t.co/hCSkbhkdPB